## Supplementary material


### CRISPR-screen

![
**EVOS Fluorescent Microscope Image Capture.**
A. HepG2_lentiV2_Ctrl with no-viral transduction.
B. HepG2_lentiV2 with viral transduction.
<!--  -->
](images/crispr/figure1.png "EVOS Fluorescent Microscope Image Capture"){#fig:sup:crispr:fig1 width="80%"}


![
**Fluorescence-Activated Cell Sorting Gate Setting.**
A. HepG2_UnStained WT.
B. HepG2_lentiV2 with viral transduction.
<!--  -->
](images/crispr/figure2.png "Fluorescence-Activated Cell Sorting Gate Setting"){#fig:sup:crispr:fig2 width="80%"}


![
**Verification of sgRNA cassette and lentiV2 transgene.**
A. 20nt sgRNA cassette was verified in lentiV2 transduced genomic DNA population, 163 bp PCR product obtained, while WT HepG2 didn’t possess the cassette, thus, no PCR product.
B. lentiviral-specific transgene WPRE was verified in lentiV2 transduced genomic DNA population, while no transduced WT didn’t have the transgene, therefore, no 173 bp PCR product observed.
<!--  -->
](images/crispr/figure3.png "Verification of sgRNA cassette and lentiV2 transgene"){#fig:sup:crispr:fig3 width="80%"}


![
<!-- **XXX.** -->
<!--  -->
<!--  -->
](images/crispr/table1.png "Table 1"){#fig:sup:crispr:table1 width="80%"}


![
**Illumina library generation.**
A. Construct for generating illumina libraries.
B. Final illumina library from HS DNA ---showed a single ~285bp peak was generated.
](images/crispr/figure4.png "xxxx"){#fig:sup:crispr:fig4 width="80%"}


### LV603

<!-- LV603:multiplier_pathways:start -->
| Pathway                             | AUC   | FDR      |
|:------------------------------------|:------|:---------|
| IRIS Neutrophil-Resting             | 0.91  | 4.51e-35 |
| SVM Neutrophils                     | 0.98  | 1.43e-09 |
| PID IL8CXCR2 PATHWAY                | 0.81  | 7.04e-03 |
| SIG PIP3 SIGNALING IN B LYMPHOCYTES | 0.77  | 1.95e-02 |

Table: Pathways aligned to LV603. {#tbl:sup:multiplier_pathways:lv603}
<!-- LV603:multiplier_pathways:end -->

<!-- LV603:phenomexcan_traits_assocs:start -->
| Trait description                  | Sample size   | Cases   | FDR      |
|:-----------------------------------|:--------------|:--------|:---------|
| Myeloid White Cell Count           | 173,480       |         | 3.63e-07 |
| Sum Basophil Neutrophil Count      | 173,480       |         | 4.07e-07 |
| Neutrophil Count                   | 173,480       |         | 4.17e-07 |
| Sum Neutrophil Eosinophil Count    | 173,480       |         | 4.72e-07 |
| Granulocyte Count                  | 173,480       |         | 5.16e-07 |
| White Blood Cell Count             | 173,480       |         | 2.67e-06 |
| Neutrophill count                  | 349,856       |         | 1.58e-05 |
| White blood cell (leukocyte) count | 350,470       |         | 2.06e-05 |

Table: Significant trait associations of LV603 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv603}
<!-- LV603:phenomexcan_traits_assocs:end -->

<!-- LV603:emerge_traits_assocs:start -->
| Phecode                     | Trait description   | Sample size   | Cases   | FDR   |
|:----------------------------|:--------------------|:--------------|:--------|:------|
| No significant associations |                     |               |         |       |

Table: Significant trait associations of LV603 in eMERGE. {#tbl:sup:emerge_assocs:lv603}
<!-- LV603:emerge_traits_assocs:end -->


### Gene modules enrichment for lipids gene-sets

<!-- lipids_gene_sets:modules_enriched_increase:start -->
| Gene module   | Lipids gene-set   | Leading edge      | p-value   |
|:--------------|:------------------|:------------------|:----------|
| **LV246**     | increase          | *DGAT2*, *ACACA*  | 0.0035    |
| LV702         | increase          | *ACACA*, *DGAT2*  | 0.0046    |
| **LV607**     | increase          | *ACACA*, *DGAT2*  | 0.0058    |
| LV890         | increase          | *ACACA*, *DGAT2*  | 0.0067    |
| **LV74**      | increase          | *MBTPS1*, *DGAT2* | 0.0078    |
| **LV865**     | increase          | *ACACA*, *DGAT2*  | 0.0092    |
| LV841         | increase          | *ACACA*, *DGAT2*  | 0.0096    |

Table: Gene modules (LVs) nominally enriched for the lipids-increasing gene-set from the CRISPR-screen (*P* < 0.01). LVs significantly aligned with pathways (FDR < 0.05) from the MultiPLIER models are shown in boldface. {#tbl:sup:lipids_crispr:modules_enriched_increase}
<!-- lipids_gene_sets:modules_enriched_increase:end -->


<!-- lipids_gene_sets:modules_enriched_decrease:start -->
| Gene module   | Lipids gene-set   | Leading edge       | p-value   |
|:--------------|:------------------|:-------------------|:----------|
| LV520         | decrease          | *FBXW7*, *TCF7L2*  | 0.0006    |
| LV801         | decrease          | *UBE2J2*, *TCF7L2* | 0.0022    |
| LV512         | decrease          | *FBXW7*, *TCF7L2*  | 0.0025    |
| **LV612**     | decrease          | *PTEN*, *FBXW7*    | 0.0036    |
| LV41          | decrease          | *PCYT2*, *TCF7L2*  | 0.0041    |
| **LV838**     | decrease          | *UBE2J2*, *TCF7L2* | 0.0070    |
| LV302         | decrease          | *TCF7L2*, *PTEN*   | 0.0083    |
| LV959         | decrease          | *TCF7L2*, *PTEN*   | 0.0092    |

Table: Gene modules (LVs) nominally enriched for the lipids-decreasing gene-set from the CRISPR-screen (*P* < 0.01). LVs significantly aligned with pathways (FDR < 0.05) from the MultiPLIER models are shown in boldface. {#tbl:sup:lipids_crispr:modules_enriched_decrease}
<!-- lipids_gene_sets:modules_enriched_decrease:end -->


### LV246

<!-- LV246:multiplier_pathways:start -->
| Pathway                                                        | AUC   | FDR      |
|:---------------------------------------------------------------|:------|:---------|
| REACTOME FATTY ACID TRIACYLGLYCEROL AND KETONE BODY METABOLISM | 0.89  | 3.97e-16 |
| REACTOME METABOLISM OF LIPIDS AND LIPOPROTEINS                 | 0.67  | 1.14e-08 |
| REACTOME TRIGLYCERIDE BIOSYNTHESIS                             | 0.86  | 6.52e-04 |
| KEGG PYRUVATE METABOLISM                                       | 0.82  | 2.66e-03 |
| KEGG PROPANOATE METABOLISM                                     | 0.83  | 4.27e-03 |

Table: Pathways aligned to LV246 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv246}
<!-- LV246:multiplier_pathways:end -->

<!-- LV246:phenomexcan_traits_assocs:start -->
| Trait description                                        | Sample size   | Cases   | FDR      |
|:---------------------------------------------------------|:--------------|:--------|:---------|
| CH2DB NMR                                                | 24,154        |         | 1.05e-12 |
| High cholesterol (self-reported)                         | 361,141       | 43,957  | 7.78e-07 |
| Ankle spacing width                                      | 206,589       |         | 2.06e-05 |
| Ankle spacing width (right)                              | 114,614       |         | 9.03e-05 |
| HDL Cholesterol NMR                                      | 19,270        |         | 2.46e-04 |
| Cholesterol lowering medication                          | 193,148       | 24,247  | 2.54e-04 |
| Ankle spacing width (left)                               | 114,630       |         | 5.39e-04 |
| Fasting Glucose                                          | 46,186        |         | 1.90e-03 |
| Cholesterol lowering medication                          | 165,340       | 38,057  | 6.74e-03 |
| Pulse rate, automated reading                            | 340,162       |         | 8.61e-03 |
| Recent easy annoyance or irritability                    | 117,483       |         | 1.04e-02 |
| Treatment/medication code: simvastatin                   | 361,141       | 40,921  | 1.11e-02 |
| Pulse rate                                               | 118,850       |         | 1.19e-02 |
| Mean platelet (thrombocyte) volume                       | 350,470       |         | 1.37e-02 |
| Duration of moderate activity                            | 268,826       |         | 1.69e-02 |
| LDL Cholesterol NMR                                      | 13,527        |         | 1.94e-02 |
| Red blood cell (erythrocyte) distribution width          | 350,473       |         | 1.99e-02 |
| Intra-ocular pressure, corneal-compensated (right)       | 76,630        |         | 2.63e-02 |
| Heel bone mineral density (BMD) (right)                  | 114,552       |         | 2.74e-02 |
| Triglycerides NMR                                        | 21,559        |         | 3.47e-02 |
| Heel bone mineral density T-score, automated (right)     | 114,614       |         | 3.75e-02 |
| Heel quantitative ultrasound index, direct entry (right) | 114,614       |         | 3.75e-02 |
| Days/week of moderate physical activity 10+ minutes      | 343,943       |         | 4.85e-02 |
| Ischaemic heart disease (wide definition)                | 361,194       | 20,857  | 4.97e-02 |

Table: Significant trait associations of LV246 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv246}
<!-- LV246:phenomexcan_traits_assocs:end -->

<!-- LV246:emerge_traits_assocs:start -->
| Phecode   | Trait description          | Sample size   | Cases   | FDR      |
|:----------|:---------------------------|:--------------|:--------|:---------|
| 276.41    | Acidosis                   | 41,838        | 1,526   | 2.40e-03 |
| 276.4     | Acid-base balance disorder | 42,005        | 1,693   | 2.97e-03 |

Table: Significant trait associations of LV246 in eMERGE. {#tbl:sup:emerge_assocs:lv246}
<!-- LV246:emerge_traits_assocs:end -->


### LV116

<!-- LV116:multiplier_pathways:start -->
| Pathway                                              | AUC   | FDR      |
|:-----------------------------------------------------|:------|:---------|
| REACTOME INTERFERON SIGNALING                        | 0.84  | 3.48e-09 |
| SVM Macrophages M1                                   | 0.92  | 2.09e-05 |
| REACTOME INTERFERON ALPHA BETA SIGNALING             | 0.94  | 3.36e-05 |
| REACTOME CYTOKINE SIGNALING IN IMMUNE SYSTEM         | 0.67  | 1.53e-04 |
| IRIS DendriticCell-LPSstimulated                     | 0.65  | 1.09e-03 |
| KEGG CYTOSOLIC DNA SENSING PATHWAY                   | 0.84  | 3.22e-03 |
| REACTOME NEGATIVE REGULATORS OF RIG I MDA5 SIGNALING | 0.81  | 1.61e-02 |

Table: Pathways aligned to LV116 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv116}
<!-- LV116:multiplier_pathways:end -->


### LV931

![
**Cell types for LV931.**
<!--  -->
](images/lvs_analysis/lv931/lv931-cell_types.svg "Cell types for LV931"){#fig:sup:lv931 width="80%"}


<!-- LV931:multiplier_pathways:start -->
| Pathway          | AUC   | FDR      |
|:-----------------|:------|:---------|
| MIPS SPLICEOSOME | 0.63  | 3.13e-02 |
| PID TGFBRPATHWAY | 0.71  | 3.99e-02 |

Table: Pathways aligned to LV931 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv931}
<!-- LV931:multiplier_pathways:end -->


### LV66

![
**Cell types for LV66.**
<!--  -->
](images/lvs_analysis/lv66/lv66-cell_types.svg "Cell types for LV66"){#fig:sup:lv66 width="80%"}

<!-- LV66:multiplier_pathways:start -->
| Pathway                                        | AUC   | FDR      |
|:-----------------------------------------------|:------|:---------|
| REACTOME METABOLISM OF LIPIDS AND LIPOPROTEINS | 0.62  | 3.12e-04 |

Table: Pathways aligned to LV66 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv66}
<!-- LV66:multiplier_pathways:end -->


### Cluster-specific and general transcriptional processes associated with disease

![
**Cluster-specific and general transcriptional processes associated with disease using novel LVs.**
The plot shows a submatrix of $\hat{\mathbf{M}}$ for the main trait clusters at $k$=29, considering only LVs (rows) that are not aligned with any pathway.
Standardized values from -6 (lighter color) to 21 (darker color).
](images/clustering/global_clustermap-novel-plain.svg "Heatmap with novel gene modules and traits"){#fig:sup:clustering:novel:heatmap width="100%"}


### LV928

![
**Cell types for LV928.**
<!--  -->
](images/lvs_analysis/lv928/lv928-cell_types.svg "Cell types for LV928"){#fig:sup:lv928 width="80%"}

<!-- LV928:multiplier_pathways:start -->
| Pathway   | AUC   | FDR      |
|:----------|:------|:---------|
| DMAP ERY3 | 0.81  | 1.16e-24 |
| DMAP ERY4 | 0.78  | 2.49e-17 |

Table: Pathways aligned to LV928 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv928}
<!-- LV928:multiplier_pathways:end -->

<!-- LV928:phenomexcan_traits_assocs:start -->
| Trait description                               | Sample size   | Cases   | FDR      |
|:------------------------------------------------|:--------------|:--------|:---------|
| Mean sphered cell volume                        | 344,729       |         | 2.18e-46 |
| Mean reticulocyte volume                        | 344,728       |         | 4.08e-44 |
| Mean corpuscular volume                         | 350,473       |         | 5.57e-33 |
| Red blood cell (erythrocyte) distribution width | 350,473       |         | 7.62e-31 |
| Reticulocyte percentage                         | 344,728       |         | 2.12e-29 |
| Reticulocyte count                              | 344,729       |         | 6.88e-28 |
| Reticulocyte Count                              | 173,480       |         | 1.06e-23 |
| Mean corpuscular haemoglobin                    | 350,472       |         | 7.89e-23 |
| High light scatter reticulocyte count           | 344,729       |         | 3.05e-21 |
| Immature reticulocyte fraction                  | 344,728       |         | 5.04e-21 |
| High light scatter reticulocyte percentage      | 344,729       |         | 1.57e-16 |
| Red blood cell (erythrocyte) count              | 350,475       |         | 2.53e-16 |
| Red Blood Cell Count                            | 173,480       |         | 2.62e-09 |
| Haemoglobin concentration                       | 350,474       |         | 1.25e-03 |
| Haematocrit percentage                          | 350,475       |         | 3.77e-03 |

Table: Significant trait associations of LV928 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv928}
<!-- LV928:phenomexcan_traits_assocs:end -->

<!-- LV928:emerge_traits_assocs:start -->
| Phecode   | Trait description                                | Sample size   | Cases   | FDR      |
|:----------|:-------------------------------------------------|:--------------|:--------|:---------|
| 250.24    | Type 2 diabetes with neurological manifestations | 43,236        | 2,963   | 1.44e-02 |
| 195       | Cancer, suspected or other                       | 50,040        | 2,250   | 2.42e-02 |
| 514.2     | Solitary pulmonary nodule                        | 50,389        | 2,270   | 4.65e-02 |

Table: Significant trait associations of LV928 in eMERGE. {#tbl:sup:emerge_assocs:lv928}
<!-- LV928:emerge_traits_assocs:end -->




### LV30

![
**Cell types for LV30.**
<!--  -->
](images/lvs_analysis/lv30/lv30-cell_types.svg "Cell types for LV30"){#fig:sup:lv30 width="80%"}

<!-- LV30:multiplier_pathways:start -->
| Pathway   | AUC   | FDR      |
|:----------|:------|:---------|
| DMAP ERY3 | 0.95  | 5.62e-52 |
| DMAP ERY4 | 0.98  | 5.28e-51 |
| DMAP ERY5 | 0.98  | 1.96e-49 |

Table: Pathways aligned to LV30 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv30}
<!-- LV30:multiplier_pathways:end -->

<!-- LV30:phenomexcan_traits_assocs:start -->
| Trait description                          | Sample size   | Cases   | FDR      |
|:-------------------------------------------|:--------------|:--------|:---------|
| Mean reticulocyte volume                   | 344,728       |         | 1.41e-51 |
| Immature reticulocyte fraction             | 344,728       |         | 5.79e-40 |
| Mean sphered cell volume                   | 344,729       |         | 3.26e-36 |
| Mean corpuscular volume                    | 350,473       |         | 3.18e-35 |
| Reticulocyte percentage                    | 344,728       |         | 1.41e-28 |
| Mean corpuscular haemoglobin               | 350,472       |         | 3.72e-28 |
| High light scatter reticulocyte count      | 344,729       |         | 8.20e-28 |
| Reticulocyte count                         | 344,729       |         | 2.13e-26 |
| Reticulocyte Count                         | 173,480       |         | 1.11e-24 |
| High light scatter reticulocyte percentage | 344,729       |         | 4.05e-22 |

Table: Significant trait associations of LV30 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv30}
<!-- LV30:phenomexcan_traits_assocs:end -->

<!-- LV30:emerge_traits_assocs:start -->
| Phecode                     | Trait description   | Sample size   | Cases   | FDR   |
|:----------------------------|:--------------------|:--------------|:--------|:------|
| No significant associations |                     |               |         |       |

Table: Significant trait associations of LV30 in eMERGE. {#tbl:sup:emerge_assocs:lv30}
<!-- LV30:emerge_traits_assocs:end -->


### LV730

![
**Cell types for LV730.**
<!--  -->
](images/lvs_analysis/lv730/lv730-cell_types.svg "Cell types for LV730"){#fig:sup:lv730 width="80%"}

<!-- LV730:multiplier_pathways:start -->
| Pathway    | AUC   | FDR      |
|:-----------|:------|:---------|
| DMAP MEGA2 | 0.82  | 2.64e-05 |

Table: Pathways aligned to LV730 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv730}
<!-- LV730:multiplier_pathways:end -->

<!-- LV730:phenomexcan_traits_assocs:start -->
| Trait description                  | Sample size   | Cases   | FDR      |
|:-----------------------------------|:--------------|:--------|:---------|
| Platelet distribution width        | 350,470       |         | 2.88e-13 |
| Mean platelet (thrombocyte) volume | 350,470       |         | 7.26e-13 |
| Platelet count                     | 350,474       |         | 1.24e-07 |
| Platelet Count                     | 173,480       |         | 1.21e-06 |
| Platelet crit                      | 350,471       |         | 1.38e-04 |

Table: Significant trait associations of LV730 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv730}
<!-- LV730:phenomexcan_traits_assocs:end -->

<!-- LV730:emerge_traits_assocs:start -->
| Phecode                     | Trait description   | Sample size   | Cases   | FDR   |
|:----------------------------|:--------------------|:--------------|:--------|:------|
| No significant associations |                     |               |         |       |

Table: Significant trait associations of LV730 in eMERGE. {#tbl:sup:emerge_assocs:lv730}
<!-- LV730:emerge_traits_assocs:end -->



### LV598

![
**Cell types for LV598.**
<!--  -->
](images/lvs_analysis/lv598/lv598-cell_types.svg "Cell types for LV598"){#fig:sup:lv598 width="80%"}

<!-- LV598:multiplier_pathways:start -->
| Pathway                     | AUC   | FDR      |
|:----------------------------|:------|:---------|
| PID SYNDECAN 1 PATHWAY      | 0.81  | 1.20e-02 |
| REACTOME COLLAGEN FORMATION | 0.77  | 1.89e-02 |

Table: Pathways aligned to LV598 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv598}
<!-- LV598:multiplier_pathways:end -->

<!-- LV598:phenomexcan_traits_assocs:start -->
| Trait description           | Sample size   | Cases   | FDR      |
|:----------------------------|:--------------|:--------|:---------|
| 6mm strong meridian (right) | 66,256        |         | 3.21e-07 |
| 6mm weak meridian (right)   | 66,256        |         | 2.04e-06 |
| 6mm strong meridian (left)  | 65,551        |         | 2.44e-06 |
| 3mm strong meridian (left)  | 75,398        |         | 2.53e-06 |
| 6mm weak meridian (left)    | 65,551        |         | 1.20e-05 |
| 3mm weak meridian (left)    | 75,398        |         | 1.58e-05 |
| 3mm strong meridian (right) | 75,410        |         | 2.95e-05 |
| 3mm weak meridian (right)   | 75,410        |         | 3.86e-05 |

Table: Significant trait associations of LV598 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv598}
<!-- LV598:phenomexcan_traits_assocs:end -->

<!-- LV598:emerge_traits_assocs:start -->
| Phecode                     | Trait description   | Sample size   | Cases   | FDR   |
|:----------------------------|:--------------------|:--------------|:--------|:------|
| No significant associations |                     |               |         |       |

Table: Significant trait associations of LV598 in eMERGE. {#tbl:sup:emerge_assocs:lv598}
<!-- LV598:emerge_traits_assocs:end -->


### LV844

![
**Cell types for LV844.**
](images/lvs_analysis/lv844/lv844-cell_types.svg "Cell types for LV844"){#fig:sup:lv844 width="80%"}

<!-- LV844:multiplier_pathways:start -->
| Pathway                                  | AUC   | FDR      |
|:-----------------------------------------|:------|:---------|
| KEGG ANTIGEN PROCESSING AND PRESENTATION | 0.80  | 1.35e-03 |

Table: Pathways aligned to LV844 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv844}
<!-- LV844:multiplier_pathways:end -->

<!-- LV844:phenomexcan_traits_assocs:start -->
| Trait description                                     | Sample size   | Cases   | Partition/cluster number   | FDR      |
|:------------------------------------------------------|:--------------|:--------|:---------------------------|:-----------------|
| Rheumatoid Arthritis                                  | 80,799        | 19,234  | 29 / 26                    | 1.20e-57 |
| malabsorption/coeliac disease (self-reported)         | 361,141       | 1,587   | 29 / 8                     | 1.25e-43 |
| Coeliac disease                                       | 361,194       | 842     | 29 / 8                     | 1.52e-41 |
| Intestinal malabsorption (ICD10 K90)                  | 361,194       | 922     | 29 / 8                     | 5.28e-40 |
| Started insulin within one year diagnosis of diabetes | 16,415        | 1,999   | 29 / 13                    | 7.77e-38 |
| Systemic Lupus Erythematosus                          | 23,210        | 7,219   | 29 / 26                    | 6.45e-35 |
| Age diabetes diagnosed                                | 16,166        |         | 29 / 13                    | 1.92e-34 |
| Never eat: Wheat products                             | 359,777       | 9,573   | 29 / 13                    | 1.37e-31 |
| hyperthyroidism (self-reported)                       | 361,141       | 2,730   | 29 / 13                    | 3.41e-30 |
| Medication: insulin product                           | 361,141       | 3,545   | 29 / 13                    | 1.78e-25 |
| Insulin medication (females)                          | 193,148       | 1,476   | 29 / 13                    | 2.79e-23 |
| Insulin medication (males)                            | 165,340       | 2,248   | 29 / 13                    | 1.27e-20 |
| hypothyroidism (self-reported)                        | 361,141       | 17,574  | 29 / 13                    | 3.35e-20 |
| Medication: levothyroxine sodium                      | 361,141       | 14,689  | 29 / 13                    | 2.76e-19 |
| psoriasis (self-reported)                             | 361,141       | 4,192   | 29 / 13                    | 6.74e-16 |

Table: Significant trait associations of LV844 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv844}
<!-- LV844:phenomexcan_traits_assocs:end -->

<!-- LV844:emerge_traits_assocs:start -->
| Phecode   | Trait description                                                                    | Sample size   | Cases   | FDR      |
|:----------|:-------------------------------------------------------------------------------------|:--------------|:--------|:-----------------|
| 714.1     | Rheumatoid arthritis                                                                 | 49,453        | 2,541   | 1.53e-08 |
| 250.1     | Type 1 diabetes                                                                      | 42,723        | 2,450   | 3.85e-08 |
| 714       | Rheumatoid arthritis and other inflammatory polyarthropathies                        | 50,215        | 3,303   | 1.02e-06 |
| 440       | Atherosclerosis                                                                      | 47,471        | 4,993   | 6.73e-03 |
| 578.8     | Hemorrhage of rectum and anus                                                        | 47,545        | 1,991   | 6.73e-03 |
| 585.32    | End stage renal disease                                                              | 43,309        | 1,842   | 9.01e-03 |
| 440.2     | Atherosclerosis of the extremities                                                   | 45,524        | 3,046   | 1.09e-02 |
| 514.2     | Solitary pulmonary nodule                                                            | 50,389        | 2,270   | 1.39e-02 |
| 444       | Arterial embolism and thrombosis                                                     | 43,378        | 900     | 2.97e-02 |
| 440.22    | Atherosclerosis of native arteries of the extremities with intermittent claudication | 44,639        | 2,161   | 3.61e-02 |

Table: Significant trait associations of LV844 in eMERGE. {#tbl:sup:emerge_assocs:lv844}
<!-- LV844:emerge_traits_assocs:end -->


### LV155

![
**Cell types for LV155.**
<!--  -->
](images/lvs_analysis/lv155/lv155-cell_types.svg "Cell types for LV155"){#fig:sup:lv155 width="80%"}

<!-- LV155:multiplier_pathways:start -->
| Pathway                         | AUC   | FDR      |
|:--------------------------------|:------|:---------|
| KEGG AUTOIMMUNE THYROID DISEASE | 0.76  | 1.05e-01 |

Table: Pathways aligned to LV155 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv155}
<!-- LV155:multiplier_pathways:end -->

<!-- LV155:phenomexcan_traits_assocs:start -->
| Trait description                | Sample size   | Cases   | Partition/cluster number   | FDR      |
|:---------------------------------|:--------------|:--------|:---------------------------|:---------|
| hypothyroidism (self-reported)   | 361,141       | 17,574  | 29 / 13                    | 1.65e-03 |
| hyperthyroidism (self-reported)  | 361,141       | 2,730   | 29 / 13                    | 1.03e-02 |
| Medication: levothyroxine sodium | 361,141       | 14,689  | 29 / 13                    | 1.12e-02 |

Table: Significant trait associations of LV155 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv155}
<!-- LV155:phenomexcan_traits_assocs:end -->

<!-- LV155:emerge_traits_assocs:start -->
| Phecode   | Trait description       | Sample size   | Cases   | FDR      |
|:----------|:------------------------|:--------------|:--------|:---------|
| 244.2     | Acquired hypothyroidism | 45,839        | 1,155   | 5.66e-02 |

Table: Trait associations of LV155 in eMERGE. {#tbl:sup:emerge_assocs:lv155}
<!-- LV155:emerge_traits_assocs:end -->


### LV57

![
**Cell types for LV57.**
](images/lvs_analysis/lv57/lv57-cell_types.svg "Cell types for LV57"){#fig:sup:lv57 width="80%"}

<!-- LV57:multiplier_pathways:start -->
| Pathway                                | AUC   | FDR      |
|:---------------------------------------|:------|:---------|
| KEGG T CELL RECEPTOR SIGNALING PATHWAY | 0.70  | 1.26e-03 |
| SVM T cells CD4 memory activated       | 0.79  | 2.59e-03 |
| IRIS CD4Tcell-Th2-restimulated12hour   | 0.78  | 7.57e-03 |
| KEGG ALLOGRAFT REJECTION               | 1.00  | 1.09e-02 |
| Custom Treg                            | 0.98  | 1.37e-02 |
| PID NFAT TFPATHWAY                     | 0.74  | 1.52e-02 |
| IRIS MemoryTcell-RO-activated          | 0.70  | 2.87e-02 |
| KEGG AUTOIMMUNE THYROID DISEASE        | 0.78  | 8.43e-02 |

Table: Pathways aligned to LV57 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv57}
<!-- LV57:multiplier_pathways:end -->

<!-- LV57:phenomexcan_traits_assocs:start -->
| Trait description                                     | Sample size   | Cases   | Partition/cluster number   | FDR      |
|:------------------------------------------------------|:--------------|:--------|:---------------------------|:---------|
| hypothyroidism (self-reported)                        | 361,141       | 17,574  | 29 / 13                    | 7.21e-25 |
| Medication: levothyroxine sodium                      | 361,141       | 14,689  | 29 / 13                    | 3.71e-23 |
| hyperthyroidism (self-reported)                       | 361,141       | 2,730   | 29 / 13                    | 8.93e-07 |
| Started insulin within one year diagnosis of diabetes | 16,415        | 1,999   | 29 / 13                    | 6.60e-05 |
| Medication: insulin product                           | 361,141       | 3,545   | 29 / 13                    | 5.20e-04 |
| Insulin medication (females)                          | 193,148       | 1,476   | 29 / 13                    | 9.40e-04 |
| Insulin medication (males)                            | 165,340       | 2,248   | 29 / 13                    | 3.63e-03 |

Table: Significant trait associations of LV57 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv57}
<!-- LV57:phenomexcan_traits_assocs:end -->

<!-- LV57:emerge_traits_assocs:start -->
| Phecode   | Trait description                                             | Sample size   | Cases   | FDR      |
|:----------|:--------------------------------------------------------------|:--------------|:--------|:---------|
| 244       | Hypothyroidism                                                | 54,404        | 9,720   | 7.66e-09 |
| 244.4     | Hypothyroidism NOS                                            | 53,968        | 9,284   | 7.66e-09 |
| 279       | Disorders involving the immune mechanism                      | 56,771        | 3,309   | 1.07e-02 |
| 514.2     | Solitary pulmonary nodule                                     | 50,389        | 2,270   | 2.62e-02 |
| 714       | Rheumatoid arthritis and other inflammatory polyarthropathies | 50,215        | 3,303   | 3.77e-02 |

Table: Significant trait associations of LV57 in eMERGE. {#tbl:sup:emerge_assocs:lv57}
<!-- LV57:emerge_traits_assocs:end -->


### LV54

![
**Cell types for LV54.**
](images/lvs_analysis/lv54/lv54-cell_types.svg "Cell types for LV54"){#fig:sup:lv54 width="80%"}

<!-- LV54:multiplier_pathways:start -->
| Pathway                            | AUC   | FDR   |
|:-----------------------------------|:------|:------|
| No pathways significantly enriched |       |       |

Table: Pathways aligned to LV54 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv54}
<!-- LV54:multiplier_pathways:end -->

<!-- LV54:phenomexcan_traits_assocs:start -->
| Trait description                                     | Sample size   | Cases   | Partition/cluster number   | FDR      |
|:------------------------------------------------------|:--------------|:--------|:---------------------------|:---------|
| Intestinal malabsorption (ICD10 K90)                  | 361,194       | 922     | 29 / 8                     | 3.10e-25 |
| Coeliac disease                                       | 361,194       | 842     | 29 / 8                     | 4.78e-25 |
| Never eat: Wheat products                             | 359,777       | 9,573   | 29 / 13                    | 3.93e-23 |
| Systemic Lupus Erythematosus                          | 23,210        | 7,219   | 29 / 26                    | 8.16e-23 |
| Started insulin within one year diagnosis of diabetes | 16,415        | 1,999   | 29 / 13                    | 2.57e-20 |
| hyperthyroidism (self-reported)                       | 361,141       | 2,730   | 29 / 13                    | 6.70e-19 |
| Medication: insulin product                           | 361,141       | 3,545   | 29 / 13                    | 3.62e-18 |
| Age diabetes diagnosed                                | 16,166        |         | 29 / 13                    | 9.20e-18 |
| malabsorption/coeliac disease (self-reported)         | 361,141       | 1,587   | 29 / 8                     | 9.63e-15 |
| Insulin medication (males)                            | 165,340       | 2,248   | 29 / 13                    | 6.01e-14 |
| psoriasis (self-reported)                             | 361,141       | 4,192   | 29 / 13                    | 1.81e-13 |
| Rheumatoid Arthritis                                  | 80,799        | 19,234  | 29 / 26                    | 2.17e-13 |
| Insulin medication (females)                          | 193,148       | 1,476   | 29 / 13                    | 2.61e-12 |
| Medication: levothyroxine sodium                      | 361,141       | 14,689  | 29 / 13                    | 4.25e-10 |
| hypothyroidism (self-reported)                        | 361,141       | 17,574  | 29 / 13                    | 2.49e-08 |

Table: Significant trait associations of LV54 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv54}
<!-- LV54:phenomexcan_traits_assocs:end -->

<!-- LV54:emerge_traits_assocs:start -->
| Phecode   | Trait description                                             | Sample size   | Cases   | FDR      |
|:----------|:--------------------------------------------------------------|:--------------|:--------|:---------|
| 250.1     | Type 1 diabetes                                               | 42,723        | 2,450   | 1.69e-13 |
| 244       | Hypothyroidism                                                | 54,404        | 9,720   | 1.01e-05 |
| 244.4     | Hypothyroidism NOS                                            | 53,968        | 9,284   | 1.01e-05 |
| 695       | Erythematous conditions                                       | 48,347        | 4,210   | 8.54e-05 |
| 714       | Rheumatoid arthritis and other inflammatory polyarthropathies | 50,215        | 3,303   | 6.58e-04 |
| 440       | Atherosclerosis                                               | 47,471        | 4,993   | 1.90e-03 |
| 585       | Renal failure                                                 | 51,437        | 9,970   | 7.10e-03 |
| 585.33    | Chronic Kidney Disease, Stage III                             | 46,279        | 4,812   | 7.49e-03 |
| 585.32    | End stage renal disease                                       | 43,309        | 1,842   | 7.49e-03 |
| 250.6     | Polyneuropathy in diabetes                                    | 41,948        | 1,675   | 8.55e-03 |
| 250       | Diabetes mellitus                                             | 52,531        | 12,258  | 1.02e-02 |
| 285.2     | Anemia of chronic disease                                     | 39,673        | 2,606   | 1.64e-02 |
| 502       | Postinflammatory pulmonary fibrosis                           | 42,396        | 1,723   | 1.77e-02 |
| 415.1     | Acute pulmonary heart disease                                 | 49,887        | 1,857   | 1.88e-02 |
| 285.21    | Anemia in chronic kidney disease                              | 38,616        | 1,549   | 2.53e-02 |
| 585.3     | Chronic renal failure [CKD]                                   | 49,204        | 7,737   | 2.62e-02 |
| 743       | Osteoporosis, osteopenia and pathological fracture            | 55,165        | 11,990  | 2.87e-02 |
| 415.11    | Pulmonary embolism and infarction, acute                      | 49,867        | 1,837   | 3.04e-02 |
| 577       | Diseases of pancreas                                          | 60,538        | 1,795   | 3.06e-02 |
| 585.1     | Acute renal failure                                           | 46,803        | 5,336   | 3.23e-02 |
| 195       | Cancer, suspected or other                                    | 50,040        | 2,250   | 3.27e-02 |
| 289.4     | Lymphadenitis                                                 | 47,564        | 3,078   | 3.67e-02 |
| 440.2     | Atherosclerosis of the extremities                            | 45,524        | 3,046   | 4.52e-02 |

Table: Significant trait associations of LV54 in eMERGE. {#tbl:sup:emerge_assocs:lv54}
<!-- LV54:emerge_traits_assocs:end -->


### LV847

![
**Cell types for LV847.**
<!--  -->
<!--  -->
](images/lvs_analysis/lv847/lv847-cell_types.svg "Cell types for LV847"){#fig:sup:lv847 width="80%"}

<!-- LV847:phenomexcan_traits_assocs:start -->
| Trait description                                                                                           | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:------------------------------------------------------------------------------------------------------------|:--------------|:--------|:---------------------------|:---------------------|
| Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones: Blood pressure medication | 193,148       | 33,519  | 29 / 17                    | 1.95e-18             |
| Vascular/heart problems diagnosed by doctor: None of the above                                              | 360,420       | 253,565 | 29 / 17                    | 4.07e-15             |
| Vascular/heart problems diagnosed by doctor: High blood pressure                                            | 360,420       | 97,139  | 29 / 17                    | 6.99e-14             |
| Non-cancer illness code, self-reported: hypertension                                                        | 361,141       | 93,560  | 29 / 17                    | 1.48e-13             |
| Treatment/medication code: bendroflumethiazide                                                              | 361,141       | 20,196  | 29 / 17                    | 1.41e-08             |
| Medication for cholesterol, blood pressure or diabetes: Blood pressure medication                           | 165,340       | 40,987  | 29 / 17                    | 1.47e-07             |
| Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones: None of the above         | 193,148       | 133,338 | 29 / 17                    | 1.55e-06             |
| Diastolic blood pressure, automated reading                                                                 | 340,162       |         | 29 / 17                    | 3.76e-06             |
| Medication for cholesterol, blood pressure or diabetes: None of the above                                   | 165,340       | 110,372 | 29 / 17                    | 6.36e-06             |

Table: Significant trait associations of LV847 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv847}
<!-- LV847:phenomexcan_traits_assocs:end -->

<!-- LV847:emerge_traits_assocs:start -->
| Phecode   | Trait description                                              | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:---------------------------------------------------------------|:--------------|:--------|:---------------------|
| 585.32    | End stage renal disease                                        | 43,309        | 1,842   | 1.88e-08             |
| 442.1     | Aortic aneurysm                                                | 45,589        | 3,111   | 5.23e-06             |
| 411.3     | Angina pectoris                                                | 43,503        | 4,382   | 2.14e-05             |
| 415.11    | Pulmonary embolism and infarction, acute                       | 49,867        | 1,837   | 5.13e-05             |
| 416       | Cardiomegaly                                                   | 53,289        | 5,259   | 6.50e-05             |
| 415.1     | Acute pulmonary heart disease                                  | 49,887        | 1,857   | 7.28e-05             |
| 411       | Ischemic Heart Disease                                         | 54,275        | 15,154  | 5.49e-04             |
| 401.2     | Hypertensive heart and/or renal disease                        | 30,405        | 6,253   | 1.28e-03             |
| 519       | Other diseases of respiratory system, not elsewhere classified | 56,909        | 2,056   | 1.28e-03             |
| 411.8     | Other chronic ischemic heart disease, unspecified              | 44,123        | 5,002   | 1.42e-03             |
| 427.6     | Premature beats                                                | 31,575        | 2,453   | 5.65e-03             |
| 687.1     | Rash and other nonspecific skin eruption                       | 47,039        | 4,964   | 9.88e-03             |
| 185       | Cancer of prostate                                             | 52,630        | 2,815   | 1.03e-02             |
| 591       | Urinary tract infection                                        | 49,727        | 10,016  | 1.34e-02             |
| 442.11    | Abdominal aortic aneurysm                                      | 44,531        | 2,053   | 2.08e-02             |
| 427.21    | Atrial fibrillation                                            | 37,743        | 8,621   | 2.26e-02             |
| 389.1     | Sensorineural hearing loss                                     | 53,672        | 4,318   | 2.73e-02             |
| 427.2     | Atrial fibrillation and flutter                                | 37,934        | 8,812   | 4.50e-02             |

Table: Significant trait associations of LV847 in eMERGE. {#tbl:sup:emerge_assocs:lv847}
<!-- LV847:emerge_traits_assocs:end -->


### LV136

![
**Cell types for LV136.**
<!--  -->
Pulmonary microvascular endothelial cells were exposed to hypoxia for 24 hours or more [@url:https://www.ncbi.nlm.nih.gov/bioproject/PRJNA232177];
](images/lvs_analysis/lv136/lv136-cell_types.svg "Cell types for LV136"){#fig:sup:lv136 width="80%"}

<!-- LV136:phenomexcan_traits_assocs:start -->
| Trait description                                                          | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:---------------------------------------------------------------------------|:--------------|:--------|:---------------------------|:---------------------|
| 3mm strong meridian (right)                                                | 75,410        |         | 29 / 10                    | 9.19e-11             |
| 6mm strong meridian (left)                                                 | 65,551        |         | 29 / 10                    | 2.06e-09             |
| 6mm strong meridian (right)                                                | 66,256        |         | 29 / 10                    | 2.38e-09             |
| 3mm strong meridian (left)                                                 | 75,398        |         | 29 / 10                    | 1.34e-08             |
| 3mm weak meridian (right)                                                  | 75,410        |         | 29 / 10                    | 1.67e-08             |
| Coronary Artery Disease                                                    | 184,305       | 60,801  | 29 / 11                    | 1.67e-08             |
| 6mm weak meridian (right)                                                  | 66,256        |         | 29 / 10                    | 3.21e-08             |
| 3mm weak meridian (left)                                                   | 75,398        |         | 29 / 10                    | 5.20e-08             |
| 6mm weak meridian (left)                                                   | 65,551        |         | 29 / 10                    | 1.21e-07             |
| Coronary atherosclerosis                                                   | 361,194       | 14,334  | 29 / 14                    | 3.90e-06             |
| Ischaemic heart disease, wide definition                                   | 361,194       | 20,857  | 29 / 14                    | 7.22e-06             |
| Vascular/heart problems diagnosed by doctor: Heart attack                  | 360,420       | 8,288   | 29 / 14                    | 2.93e-04             |
| Myocardial infarction                                                      | 361,194       | 7,018   | 29 / 14                    | 6.33e-04             |
| Myocardial infarction, strict                                              | 361,194       | 7,018   | 29 / 14                    | 6.33e-04             |
| Diagnoses - main ICD10: I21 Acute myocardial infarction                    | 361,194       | 5,948   | 29 / 14                    | 9.92e-04             |
| Non-cancer illness code, self-reported: heart attack/myocardial infarction | 361,141       | 8,239   | 29 / 14                    | 1.40e-03             |
| Major coronary heart disease event excluding revascularizations            | 361,194       | 10,157  | 29 / 14                    | 1.85e-02             |
| Major coronary heart disease event                                         | 361,194       | 10,157  | 29 / 14                    | 1.85e-02             |
| Fasting Insulin                                                            | 38,238        |         | 29 / 11                    | 3.85e-02             |

Table: Significant trait associations of LV136 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv136}
<!-- LV136:phenomexcan_traits_assocs:end -->

<!-- LV136:emerge_traits_assocs:start -->
| Phecode   | Trait description            | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:-----------------------------|:--------------|:--------|:---------------------|
| 747.1     | Cardiac congenital anomalies | 59,198        | 1,871   | 4.71e-02             |
| 411.4     | Coronary atherosclerosis     | 52,836        | 13,715  | 4.80e-02             |

Table: Significant trait associations of LV136 in eMERGE. {#tbl:sup:emerge_assocs:lv136}
<!-- LV136:emerge_traits_assocs:end -->


### LV93

![
**Cell types for LV93.**
<!--  -->
](images/lvs_analysis/lv93/lv93-cell_types.svg "Cell types for LV93"){#fig:sup:lv93 width="80%"}

<!-- LV93:phenomexcan_traits_assocs:start -->
| Trait description   | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:--------------------|:--------------|:--------|:---------------------------|:---------------------|
| CH2DB NMR           | 24,154        |         | 29 / 16                    | 9.61e-24             |
| Chronotype          | 128,266       |         | 29 / 16                    | 1.17e-03             |
| HDL Cholesterol NMR | 19,270        |         | 29 / 16                    | 2.99e-03             |

Table: Significant trait associations of LV93 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv93}
<!-- LV93:phenomexcan_traits_assocs:end -->

<!-- LV93:emerge_traits_assocs:start -->
| Phecode   | Trait description                  | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:-----------------------------------|:--------------|:--------|:---------------------|
| 208       | Benign neoplasm of colon           | 55,694        | 8,597   | 6.21e-03             |
| 440.2     | Atherosclerosis of the extremities | 45,524        | 3,046   | 1.31e-02             |
| 444       | Arterial embolism and thrombosis   | 43,378        | 900     | 4.06e-02             |

Table: Significant trait associations of LV93 in eMERGE. {#tbl:sup:emerge_assocs:lv93}
<!-- LV93:emerge_traits_assocs:end -->


### LV206

![
**Cell types for LV206.**
<!--  -->
](images/lvs_analysis/lv206/lv206-cell_types.svg "Cell types for LV206"){#fig:sup:lv206 width="80%"}

<!-- LV206:phenomexcan_traits_assocs:start -->
| Trait description   | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:--------------------|:--------------|:--------|:---------------------------|:---------------------|
| CH2DB NMR           | 24,154        |         | 29 / 16                    | 7.67e-21             |
| HDL Cholesterol NMR | 19,270        |         | 29 / 16                    | 6.46e-03             |

Table: Significant trait associations of LV206 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv206}
<!-- LV206:phenomexcan_traits_assocs:end -->

<!-- LV206:emerge_traits_assocs:start -->
| Phecode   | Trait description            | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:-----------------------------|:--------------|:--------|:---------------------|
| 458       | Hypotension                  | 51,341        | 4,432   | 1.41e-02             |
| 286.9     | Abnormal coagulation profile | 48,006        | 800     | 1.54e-02             |
| 458.9     | Hypotension NOS              | 50,150        | 3,241   | 1.58e-02             |
| 428.2     | Heart failure NOS            | 48,178        | 3,584   | 1.65e-02             |

Table: Significant trait associations of LV206 in eMERGE. {#tbl:sup:emerge_assocs:lv206}
<!-- LV206:emerge_traits_assocs:end -->


### LV260

![
**Cell types for LV260.**
<!--  -->
](images/lvs_analysis/lv260/lv260-cell_types.svg "Cell types for LV260"){#fig:sup:lv260 width="80%"}

<!-- LV260:phenomexcan_traits_assocs:start -->
| Trait description   | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:--------------------|:--------------|:--------|:---------------------------|:---------------------|
| CH2DB NMR           | 24,154        |         | 29 / 16                    | 5.96e-17             |
| HDL Cholesterol NMR | 19,270        |         | 29 / 16                    | 2.37e-02             |

Table: Significant trait associations of LV260 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv260}
<!-- LV260:phenomexcan_traits_assocs:end -->

<!-- LV260:emerge_traits_assocs:start -->
| Phecode   | Trait description   | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:--------------------|:--------------|:--------|:---------------------|
| 427.6     | Premature beats     | 31,575        | 2,453   | 2.85e-02             |
| 426.3     | Bundle branch block | 31,827        | 2,705   | 4.80e-02             |

Table: Significant trait associations of LV260 in eMERGE. {#tbl:sup:emerge_assocs:lv260}
<!-- LV260:emerge_traits_assocs:end -->


### LV21

![
**Cell types for LV21.**
<!--  -->
](images/lvs_analysis/lv21/lv21-cell_types.svg "Cell types for LV21"){#fig:sup:lv21 width="80%"}

<!-- LV21:phenomexcan_traits_assocs:start -->
| Trait description   | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:--------------------|:--------------|:--------|:---------------------------|:---------------------|
| Alzheimers Disease  | 54,162        | 17,008  | 29 / 16                    | 1.64e-19             |
| LDL Cholesterol NMR | 13,527        |         | 29 / 16                    | 1.18e-04             |
| Triglycerides NMR   | 21,559        |         | 29 / 16                    | 2.19e-02             |

Table: Significant trait associations of LV21 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv21}
<!-- LV21:phenomexcan_traits_assocs:end -->

<!-- LV21:emerge_traits_assocs:start -->
| Phecode   | Trait description        | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:-------------------------|:--------------|:--------|:---------------------|
| 573       | Other disorders of liver | 47,826        | 2,524   | 1.37e-02             |
| 577       | Diseases of pancreas     | 60,538        | 1,795   | 2.15e-02             |

Table: Significant trait associations of LV21 in eMERGE. {#tbl:sup:emerge_assocs:lv21}
<!-- LV21:emerge_traits_assocs:end -->


### LV5

![
**Cell types for LV5.**
<!--  -->
](images/lvs_analysis/lv5/lv5-cell_types.svg "Cell types for LV5"){#fig:sup:lv5 width="80%"}

<!-- LV5:phenomexcan_traits_assocs:start -->
| Trait description                                                                      | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:---------------------------------------------------------------------------------------|:--------------|:--------|:---------------------------|:---------------------|
| LDL Cholesterol NMR                                                                    | 13,527        |         | 29 / 16                    | 1.78e-04             |
| Triglycerides NMR                                                                      | 21,559        |         | 29 / 16                    | 5.00e-04             |
| Alzheimers Disease                                                                     | 54,162        | 17,008  | 29 / 16                    | 3.06e-03             |
| Ever had prolonged feelings of sadness or depression                                   | 117,763       | 64,374  | 29 / 27                    | 8.69e-03             |
| Substances taken for depression: Medication prescribed to you (for at least two weeks) | 117,763       | 28,351  | 29 / 27                    | 1.03e-02             |
| Recent feelings of depression                                                          | 117,656       |         | 29 / 27                    | 1.32e-02             |
| Ever contemplated self-harm                                                            | 117,610       |         | 29 / 27                    | 1.89e-02             |
| Recent lack of interest or pleasure in doing things                                    | 117,757       |         | 29 / 27                    | 2.08e-02             |
| Amount of alcohol drunk on a typical drinking day                                      | 108,256       |         | 29 / 27                    | 3.50e-02             |
| Ever sought or received professional help for mental distress                          | 117,677       | 46,020  | 29 / 27                    | 3.92e-02             |
| General happiness                                                                      | 117,442       |         | 29 / 27                    | 4.74e-02             |

Table: Significant trait associations of LV5 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv5}
<!-- LV5:phenomexcan_traits_assocs:end -->

<!-- LV5:emerge_traits_assocs:start -->
| Phecode   | Trait description            | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:-----------------------------|:--------------|:--------|:---------------------|
| 241       | Nontoxic nodular goiter      | 47,842        | 3,158   | 8.98e-03             |
| 241.1     | Nontoxic uninodular goiter   | 47,125        | 2,441   | 2.57e-02             |
| 241.2     | Nontoxic multinodular goiter | 46,465        | 1,781   | 4.43e-02             |

Table: Significant trait associations of LV5 in eMERGE. {#tbl:sup:emerge_assocs:lv5}
<!-- LV5:emerge_traits_assocs:end -->


### LV434

![
**Cell types for LV434.**
<!--  -->
<!-- `FIXME:`{.red} create a section for all LVs and clarify how figures were generated, like: -->
<!-- The top samples in human breast cancer cells have larger LV values that were thresholded at 3.0 for visualization purposes. -->
<!--  -->
HEK293 is a cell line derived from human embryonic kidney cells;
3T3 is a cell line derived from mouse embryonic fibroblasts.
](images/lvs_analysis/lv434/lv434-cell_types.svg "Cell types for LV434"){#fig:sup:lv434 width="80%"}

<!-- LV434:phenomexcan_traits_assocs:start -->
| Trait description                        | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:-----------------------------------------|:--------------|:--------|:---------------------------|:---------------------|
| Attention Deficit Hyperactivity Disorder | 53,293        | 19,099  | 29 / 21                    | 7.01e-03             |

Table: Significant trait associations of LV434 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv434}
<!-- LV434:phenomexcan_traits_assocs:end -->

<!-- LV434:emerge_traits_assocs:start -->
| Phecode   | Trait description                        | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:-----------------------------------------|:--------------|:--------|:---------------------|
| 722       | Intervertebral disc disorders            | 47,659        | 7,458   | 6.65e-03             |
| 721       | Spondylosis and allied disorders         | 47,517        | 7,316   | 7.62e-03             |
| 250.4     | Abnormal glucose                         | 45,220        | 4,947   | 1.02e-02             |
| 721.1     | Spondylosis without myelopathy           | 47,315        | 7,114   | 1.22e-02             |
| 720       | Spinal stenosis                          | 44,807        | 4,606   | 1.74e-02             |
| 288       | Diseases of white blood cells            | 47,288        | 2,802   | 2.10e-02             |
| 796       | Elevated prostate specific antigen [PSA] | 51,990        | 2,175   | 3.09e-02             |
| 288.2     | Elevated white blood cell count          | 46,595        | 2,109   | 3.54e-02             |
| 079       | Viral infection                          | 46,991        | 1,934   | 4.19e-02             |

Table: Significant trait associations of LV434 in eMERGE. {#tbl:sup:emerge_assocs:lv434}
<!-- LV434:emerge_traits_assocs:end -->


<!-- ### Top gene modules in the prediction of Niacin as a therapeutic drug

| LV        | Value for Niacin      | Value for atherosclerosis   | Difference   |
|:----------|:----------------------|:----------------------------|:-------------|

Table: Top gene modules/LVs responsible for predicting Niacin as a therapeutic drug for atherosclerosis. {#tbl:sup:emerge_assocs:lv434} -->


### Agreement of consensus clustering partitions with the ensemble by number of clusters

![
**Final selected partitions for follow-up analysis.**
<!--  -->
From all consensus clustering partitions generated with $k$ from 2 to 60, we selected those with a median adjusted Rand index (ARI) with the ensemble members greater the 75th percentile.
](images/clustering/selected_best_partitions_by_k.svg "Consensus partitions agreement with ensemble"){#fig:sup:consensus_agreement width="80%"}
